Brief Introduction:
Launched in 2025
National Class 1 New Biological Product
The first 40kD Y-shape branched PEG modified long-acting growth hormone injection in the World.
Brand new International Nonproprietary Name approved by WHO.
Indications:
Inpegsomatropin is indicated for the treatment of growth failure in children aged 3 and older due to growth hormone deficiency (GHD).